Ohio Jury Faults Pharmacies for Spurring Opioid Epidemic

November 24, 2021 by Tom Ramstack
Ohio Jury Faults Pharmacies for Spurring Opioid Epidemic

CLEVELAND, Ohio — A landmark jury verdict Tuesday could make major pharmacy chains like CVS, Walgreens and Walmart liable for encouraging the opioid epidemic that kills thousands of Americans each year. 

The verdict in federal court in Ohio is the first to uphold a legal theory underpinning about 3,000 lawsuits nationwide.

Unlike other recent judgments in Oklahoma and California state courts, the U.S. District Court in Cleveland found that the pharmacies created a “public nuisance” by selling a dangerous drug despite its known risks of addiction, overdose and death.

If the decision survives on appeal, it would vastly increase the liability for opioid complications, according to attorneys who handled the case.

The pharmacies “engaged in intentional and/or illegal conduct [that] was a substantial factor in producing the public nuisance,” according to the verdict form. 

A separate court proceeding is scheduled for the spring to determine the penalty for the pharmacies. The plaintiffs are suggesting more than $1 billion for addiction treatment of residents in the two Ohio counties that sued.

“Today’s verdict represents a milestone victory for the Lake County and Trumbull County communities, and the entire country, in the fight against the opioid epidemic,” lawyers for the plaintiffs said in a joint statement.

Lake and Trumbull county officials blamed the pharmacies for making opioids available to consumers in amounts that far exceeded their medical needs. The pharmacies’ business practices “produced a permanent or long-lasting effect upon the public right,” their Aug. 19, 2021 court filing says. 

The trial was the first to hold pharmacies responsible for the opioid epidemic and the first that represented a victory for a local government. Other lawsuits have named opioid distributors and manufacturers as defendants.

The Oklahoma Supreme Court overturned a $465 million judgment this month against pharmaceutical company Johnson & Johnson. In California this month, a judge dismissed a lawsuit against drug manufacturers that make opioids.

All three of the pharmacies said they would appeal. They argued during the trial that they complied with all laws and Food and Drug Administration regulations.

If anyone other than the patients were to be blamed, it was the doctors, they said.

“Prescribers, they have the greatest control over the spigot,” said Brian Swanson, attorney for Walgreens, during closing arguments.

A Walgreens statement said “the trial court committed significant legal errors in allowing the case to go before a jury on a flawed legal theory that is inconsistent with Ohio law.”

A Walmart statement said the trial “was engineered to favor the plaintiffs’ attorneys and was riddled with remarkable legal and factual mistakes.”

CVS officials said they “look forward to the appeals court review of this case, including the misapplication of public nuisance law.”

Tom can be reached at [email protected].

A+
a-
  • CVS
  • pharmacies
  • Walgreens
  • Walmart
  • In The News

    Health

    Voting

    Prescription Drugs

    What Do Weight Loss Drugs Mean for a Diet Industry Built on Eating Less and Exercising More?

    NEW YORK (AP) — Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds... Read More

    NEW YORK (AP) — Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds when he was in his 30s to as high as 220. He spent a decade tracking calories on WeightWatchers, but the pounds he dropped always crept... Read More

    April 24, 2024
    by Dan McCue
    FDA Approves New Treatment for Urinary Tract Infections

    WASHINGTON — The Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary... Read More

    WASHINGTON — The Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections.  “Uncomplicated UTIs are a very common condition impacting women and one of the most frequent reasons for antibiotic use,” said Dr. Peter Kim, M.S.,... Read More

    April 23, 2024
    by Beth McCue
    Study Finds Next-Gen Antibiotics Underutilized

    WASHINGTON — A new study conducted by researchers at the National Institutes of Health found clinicians frequently continue to treat... Read More

    WASHINGTON — A new study conducted by researchers at the National Institutes of Health found clinicians frequently continue to treat antibiotic-resistant infections with older generic antibiotics considered to be less effective and less safe than newer ones. Researchers examined the factors influencing doctors’ preference for older... Read More

    April 17, 2024
    by Dan McCue
    Eli Lilly Obesity Drug Appears to Ease Sleep Apnea Symptoms in Trials

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its... Read More

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its obesity drug, Zepbound, can provide considerable relief to overweight people who have sleep apnea. Though the findings have yet to be published in a peer-reviewed medical... Read More

    Many Cancer Drugs Remain Unproven Five Years After Accelerated Approval, a Study Finds

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often... Read More

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such... Read More

    ALS Drug Will Be Pulled From US Market After Study Showed Patients Didn't Benefit

    WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it... Read More

    WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and... Read More

    News From The Well
    scroll top